was performed. Four drug combinations were tested. A group of 75 cases of female primary breast cancer was assessed. Numerous correlations were found among molecular factors tested but none, with the exception of tumor grading, of these reflected ex vivo chemosensitivity of tumors tested. The results suggest that the parameters tested may not be important factors related to adjuvant chemoresponsiveness of primary human breast cancer to tested drug combinations.
Breast cancer is still a leading cause of death among women concerning the neoplasmic disease around the world. Patients with operable breast cancer are primarily treated by surgery, and then by postoperative hormonal therapy, radiotherapy and/or chemotherapy, with the exception of patients with early-stage disease. The necessity of choosing a good adjuvant treatment for breast cancer patients, e.g. an effective chemotherapy regimen, is one of the key problems in the therapy. One of the ways of selecting the proper treatment is the analysis of clinicopathological data, as well as the status of some molecular factors known as having a predictive value in breast cancer, e.g. status of erbB-2 oncogene and/or its product (recently discussed by Clark, 1998) . The other factors studied in the case of breast cancer (without established predictive value, however), are other oncogenes [e.g. myc family (Ryan & Birnie, 1996) ] and serum markers, e.g. CEA and CA-15.3 antigens which, used in combination, correlate to breast cancer dissemination and may be useful markers of the effectiveness of therapy used, as well as markers of disease relapses (Molina & Gion, 1998; Robertson et al., 1999) .
It is currently accepted that cancer patients' clinical and histopathological evaluation does not provide sufficient information as regards the response to chemotherapy. Drug selection for individual patients is usually based on reported response rates for clinical trials (so-called empiric treatment), but not on ex vivo individualized chemosensitivity assays. The response rates are usually better after treatment with the ex vivo selected chemotherapy regimens than with empiric ones, however, only one third of patients entered in prospective trials of ex vivo chemosensitivity testing were treated with an ex vivo best regimen, as reviewed by Cortazar & Johnson (1999) .
In, at least, some cancer patients, more effective clinical response to chemotherapy may be achieved by selecting the most active drugs on the basis of ex vivo chemosensitivity test results for individual patients (Zabel et al., 1992; Cree & Kurbacher, 1997; Cortazar & Johnson, 1999; Kurbacher et al., 1999) . One of the ex vivo assays widely used in prediction of chemotherapy response, or in vitro drug testing in a variety of cancers, is the adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA) and its modifications (Cree & Kurbacher, 1997; . It has a high evaluability rate and its results are independent of presence of non-cancerous cells in specimens evaluated (Cree & Kurbacher, 1997; . ATP-CVA is individually able to detect the majority of patients with in vivo poor or good response to chemotherapy; its sensitivity appears to be more than 85% and its specificity not less than 80%, with the true positive predictive value of more than 92% and true negative predictive value of more than 70% (Cree & Kurbacher, 1997; De Vita, 1997; ).
As we hypothesize, even better results may be obtained when the ex vivo chemosensitivity assay will be combined with assessment of molecular factors with established or probable predictive value in individual patients with cancer. Therefore, we performed a preliminary study on the correlation of selected molecular factors [c-myc oncogene average gene copy numbers (AGCN); serum CEA and CA-15.3 antigen levels; tumor cells' DNA values] with the ex vivo chemosensitivity of ovarian cancer in the modified ATP-CVA.
PATIENTS, MATERIALS AND METHODS
A group of 75 female patients with primary, histologically confirmed, invasive breast cancer, diagnosed and treated in the Department of Obstetrics/Gynecology of the St. Elisabeth Hospital, Ibbenbüren, was assessed. The mean age of patients was 57.2 ± 11.4 years (mean ± S.D., range 34-81 years). The tumors assessed were classified according to the TNM classification of breast cancer. Tumor staging was: pT1: 47%, pT2: 39%, pT3: 5%, pT4: 9%. Tumor grading was as follows: G1: 4%, G2: 40%, G3 or G4: 56%. Nodal status classification was: pN0: 65%, pN1: 32%, pN2: 1%, unknown nodal status: 1%. One patient had detectable metastasis (pM0: 99%, pM1: 1%); 20% of patients were premenopausal, 7% peripausal, 73% postmenopausal.
Statistical analyses were performed using Statistica for Windows 4.3 software (Statsoft Inc., OK, USA).
c-myc Oncogene average gene copy numbers (AGCN). The AGCNs were determined using double differential polymerase chain reaction (ddPCR). The general ddPCR reaction conditions, reproducibility and clinical usefulness have been described elsewhere (Brandt et al., 1994; 1995a; 1995b) , and we used the ddPCR and electrophoresis conditions exactly as previously described (Vogt et al., 1998a) . Primers for SOD2 and HBB (Brandt et al., 1995a) , and for c-myc (Beckmann et al., 1999) fragments amplification have been described previously.
Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA-15.3).
The protein concentrations in serum were determined using commercially available CEA and CA-15.3 enzyme-linked immunosorbent assays (Abbott), in accordance with the manufacturer's instructions. DNA values. Tumor tissue was cut up with a scalpel to 1 ml of Partec HR-A solution (Lysing solution, Partec, Germany), then incubated for 10 min on a shaker board at room temperature. The cell suspension obtained was filtered through a 50 mm nylon mesh, 3 ml of Partec HR-B solution (Partec, Germany) was added, and the solution was incubated for 10 min at room temperature (DAPI-Staining). Analysis was performed directly with the Partec PAS Flow-Cytometry Analyzer using the HBO-Lamp excitation and Modfit or DPAC-Software for Cell Cycle Analysis and Ploidy Determination. The diploid region was defined as a DNA index from 0.95 to 1.05 and the tetraploid region as being from 1.9 to 2.1.
Adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA). For ATP-CVA, a slightly modified method of Andreotti et al. was used (1994; . Fresh breast cancer tissue specimens were treated as described by Vogt et al. (1999a) . Therapeutic drug preparations from commercial sources were stored and used before expiration dates according to the manufacturer's instructions. Four drug combinations were tested: 1 -cyclophosphamide/metotrexate/ 5-fluorouracil (CMF), 62 cancer cell cultures were tested; 2 -5-fluorouracil/epirubicin/ cyclophosphamide (FEC), 65 cancer cell cultures were tested; 3 -paclitaxel/epirubicin (PE), 67 cancer cell cultures were tested; 4 -paclitaxel/mitoxantrone (PMi), 47 cancer cell cultures were tested. Cyclophosphamide was used in all cases as its active metabolite, 4-hydroxycyclophosphamide. The drugs were used in six dilutions, corresponding to 200%, 100%, 50%, 25%, 12.5% and 6.25% of each drug standard test drug concentration (TDC). 100% TDC values used were as follows: 4-hydroxycyclophosphamide 3.0 mg/ml, metotrexate 2.8 mg/ml, 5-fluorouracil 22.5 mg/ml, epirubicin 0.5 mg/ml, paclitaxel 13.6 mg/ml, mitoxantrone 0.65 mg/ml) Kurbacher et al., 1996a) . Each measurement was performed in triplicate. Percentages of total growth inhibition (TGI) were calculated according to the formula: 1-(MR-MI)/(MO-MI)´100 = %TGI; where: Vol. 47 Chemosensitivity of breast cancer ex vivo 151 MR = mean counts for replicate test drug cultures; MI = mean counts for maximum inhibition control cultures; MO = mean counts for no inhibition control cultures. Areas under response curves (AUC) values for percentage tumor growth inhibition vs test drug concentration were calculated using the trapezoidal rule.
RESULTS AND DISCUSSION
The descriptive results of the determination of selected molecular factors in the patients studied are presented in Table 1 . Some interesting statistically significant relationships among the patients' and tumor parameters were found and summarized in Table 2 .
The c-myc gene amplification determined by ddPCR was found in 24 cases (32.0%) (according to the published cut-off value of AGCN > 2.0) (Berns et al., 1995) . A correlation between c-myc amplification status and patients' age was found (p = 0.047 in Mann-Whitney U test; c-myc AGCN correlation with patients' age: p = 0.035 in Spearman rank order correlation, Spearman R = 0.24). This result is the opposite of that obtained by us in a study of ovarian cancer (Vogt et al., accompanying paper) and was not known to us from published data. We also found a negative correlation between c-myc amplification status and fraction of cells in G Table 3 .
The most effective drug regimen in the study was the PMi combination, giving the mean AUC of 17091, slightly less effective was the PE combination, giving the mean AUC of 16332, a worse regimen was the FEC combination, giving the mean AUC of 14528. The least effective regimen was the CMF combination, giving the mean AUC of 10735. In the study, all the ex vivo chemosensitivity results (expressed as AUCs) correlate strictly with each other (Table 4) , despite the reported great variability in the effectivity of single drugs and drug combinations in breast cancer Vol. 47 Chemosensitivity of breast cancer ex vivo 153 Kurbacher et al., 1996a; 1996b; , or for chemosensitivity testing in breast cancer cell lines (several examples). We recently tested the combinations of ATP-CVA with cellular DNA parameters, oncogenes' gene dosage abberations and/or overexpression in a primary non-small cell lung cancer (Vogt et al., 1998b ) and ovarian cancer (Vogt et al., 1999b) . To the best of our knowledge, prior to our recent studies Schlotter et al., 1999) , ATP-CVA results in breast cancer have only once been correlated with molecular factors known as having a prognostic or predictive value in breast cancer, namely with p53 gene product expression, in a study which demonstrated a correlation between p53 protein expression and chemosensitivity of human breast cancer specimens (Petty et al., 1994) .
In conclusion, the lack of correlation of c-myc AGCN, c-myc amplification status, serum CEA and CA-15.3 antigen levels, or proportions of cells in various cell cycle phases with chemosensitivity to all tested drug combinations, found in the present study, may suggest that the parameters tested may not be important factors related to adjuvant chemoresponsiveness of primary human breast cancer to tested drug combinations. In order to obtain useful and valuable results of combined testing we recently analysed the combination of other molecular factors (namely erbB oncogene family gene dosages and erbB-2 expression) with ATP-CVA in the breast cancer . The results of the study are promising and suggest that erbB-2 expression (but not erbB family gene aberrations), may be effectively combined in ex vivo chemoresponsiveness prediction of primary human breast cancer, but this preliminary suggestion awaits further clinical confirmation. 
